![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Results of Auspex Pharmaceuticals' Phase 3 Registration Trial of SD-809 to be Presented at AAN Annual Meeting
27 mars 2015 07h00 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., March 27, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for people...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Pharmaceuticals Reports Fourth Quarter 2014 Results and Business Highlights
16 mars 2015 16h01 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for people...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex to Present at the Cowen Healthcare Conference
23 févr. 2015 06h30 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Pharmaceuticals Completes Enrollment in a Pivotal Clinical Trial of SD-809 in Tardive Dyskinesia
03 févr. 2015 06h30 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex to Present at the 2015 Leerink Global Healthcare Conference
02 févr. 2015 16h00 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
28 janv. 2015 16h00 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Announces Pricing of Follow on Offering
23 janv. 2015 07h27 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Announces Proposed Public Offering of Common Stock
21 janv. 2015 16h32 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population
14 janv. 2015 13h34 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 14, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
![Auspex Pharmaceuticals logo](/news-release/logo/309081/0/309081.jpg?lastModified=12%2F09%2F2016%2023%3A04%3A24&size=2)
Auspex Pharmaceuticals Announces SD-1077 Program for the Potential Treatment of Parkinson's Disease and Related Movement Disorders
12 janv. 2015 09h19 HE
|
Auspex Pharmaceuticals, Inc.
Auspex to Acquire Remaining Worldwide Rights to SD-1077 Through Purchase of Imphar AG
Clinical Proof-Of-Concept Data for SD-1077 Versus Levodopa Expected in 2016
LA JOLLA, Calif., Jan. 12, 2015...